The schizophrenia phenotype is heterogeneous with respect to clinical presentation, long-term response to medication, and outcome, possibly reflecting genetic heterogeneity and/or the presence of modifier genes.
In order to recruit subgroups of schizophrenic patients selected on the basis of medication response, we collected 105 patients carefully assessed for long-term outcome and responsiveness to conventional neuroleptics. The responder (n = 43) and nonresponder (n = 62) schizophrenic patients did not differ according to age and gender distributions. Controls were healthy volunteers, were significantly older and included more females. In keeping with the study design, the two groups of patients differed significantly according to the severity of psychotic symptoms at the time of evaluation, the percent of time spent as inpatients since their first contact with the psychiatric institution and their age at first contact with psychiatric care facilities (see Table 1 ).
Compared to controls, allele T of the MTHFR gene was significantly more frequent in schizophrenic patients collapsed as one sample (R + NR) ( 2 = 5.98, df = 1, P = 0.014). The most striking finding was observed when the distribution of allelic frequencies was reanalyzed according to quality of therapeutic response to conventional neuroleptics and long-term outcome. The group of responder patients showed a highly significant increase in the frequency of allele T ( 2 = 17.52, df = 1, P = 0.00003) in contrast to the group of nonresponder patients ( 2 = 0.10, df = 1, P = 0.74). The odds ratio associated with allele T (carrying at least one allele T) in the group of responder patients was 5.86 with a 95% confidence interval of [2.19, 15 .70]. The attributable fraction associated with carry- 48.9 ± 9.0 24.4 ± 3.9** Age at 1 C = age at first contact with a psychiatric care facility; U = undifferentiated; P = paranoid; D = disorganized; C = catatonic; BPRS = Brief psychiatric rating scale. **PϽ0.01.
ing a T allele in the group of responder patients was 75%, reflecting both the strength of the association and the high frequency of the T allele in the general population. The same pattern of differences between responders and controls was observed when subjects with two French Canadian parents (FC) and those with at least one non-French Canadian (NFC) parent, were compared (FC: 2 = 9.40, df = 1, P = 0.002; NFC: 2 = 6.8, df = 1, P = 0.009). Reanalysis per gender resulted in a significant difference in males ( 2 = 12.77, df = 1, P = 0.0003), but only a trend in females ( 2 = 2.82, df = 1, P = 0.09) (see Table 2 ).
We tested both dominant (TT + CT vs CC) and recessive (TT vs TC + CC) models and in both cases, the differences between responder patients and controls proved significant (see Table 2 ). This remained generally true when responder and controls were stratified according to the ethnic background of their parents.
MTHFR, a key regulatory enzyme in one-carbon metabolic cycles, is required for the synthesis of 5-methyltetrahydrofolate, the primary circulatory form of folate and the carbon donor for homocysteine remethylation to methionine. In its heterozygous or homozygous state, the C to T substitution correlates with reduced enzyme activity and increased thermolability in lymphocyte extracts. 5 Homozygosity for this variant of MTHFR is associated with mild hyperhomocysteinemia, particularly in individuals with low folate intake. 7 Several reports indicate that a high plasma level of homocysteine may be a risk factor for various pathological conditions, such as pregnancies complicated by neural tube defects 8 or abortions 9 and has been previously reported in schizophrenic patients. 10 Casereports of treatment of hyperhomocysteinemia and psychotic symptoms using folate 11, 12 have been described. Furthermore, some patients with homocysteinuria, an inborn error metabolism that can be caused by rare and severe mutations in the MTHFR gene, have exhibited schizophrenia-like symptoms in addition to severe hyperhomocysteinemia, hypomethioninemia and various neurological manifestations. 13 The mechanism by which the thermolabile isoform of the enzyme confers susceptibility to these conditions remains unknown. In the context of schizophrenia, several mechanisms could be postulated. It is possible that increased levels of homocysteine, usually associated with the TT genotype, affect brain development, via excitotoxic 14 or other effects, resulting in subtle brain abnormalities, predisposing to schizophrenia in later stages of development. The fact that increased levels of homocysteine in the plasma of pregnant mothers increase the risk for neural tube defects indicates that this metabolic abnormality has some negative impact on the developing nervous system. It is also possible that the T allele is associated with a disturbance in the one-carbon cycle metabolism regulated by MTHFR, since MTHFR provides the carbon group for generating the S-adenosylmethionine (SAM), a universal methyl donor. A disturbance of one-carbon metabolism may result in a deficiency of methylation reactions that are required for numerous pathways including detoxification, DNA methylation and regulation of biogenic amine metabolism. The metabolic effect of the mutated MTHFR enzyme depends on environmental factors (dietary folate), 15 which is consistent with the recently reported high prevalence of history of preeclampsia, an indicator of fetal malnutrition, in schizophrenic patients compared to normal controls. 16 In the present study, the subgroup of schizophrenic patients who were characterized by a very good response to conventional neuroleptics and who had a good long-term outcome were more frequent carriers of the missense mutation of the MTHFR gene compared to healthy volunteers and to neuroleptic nonresponders. This association was observed for both a recessive as well as a dominant model of transmission, though the latter showed more power to discriminate between responder patients and controls. Although neuroleptic responder schizophrenic females had an increased frequency of allele T, compared to control females, the difference with healthy volunteers did not reach statistical significance. This may indicate that the association is more specific to male schizophrenic patients, although any definitive conclusion with regard to gender differences may require a larger study group.
The fact that no association with the T allele was observed in the group of neuroleptic nonresponder patients (NR), supports the contention that neuroleptic-responder and -nonresponder patients may be at least partially different from a pathogenic point of view. Alternatively, but not exclusively, instead of being a disease-susceptibility factor for schizophrenia per se, allele T could be associated with the ability of neuroleptic treatment (or any other effective treatment for that matter), to reverse schizophrenia-like symptoms. Since it is proposed that an adequate control of psychotic symptoms early in the course of the disease may prevent at least in part the deteriorating course of schizophrenia, 17 it is conceivable, on the basis of the data presented above, that carriers of allele T might show a better long-term outcome/prognosis. This hypothesis could be tested in long-term prospective longitudinal studies in schizophrenia.
Finally, some caution is warranted when interpreting the results of this association study. Population-based association studies may lead to both false positives and false negatives. In spite of the fact that all patients in this study were Caucasians, it is still possible that population stratification biases might have occurred in this sample. However, the fact that a statistically significant difference between responder patients and controls of French Canadian ancestry was observed, reduces the likelihood of population stratification bias, though it does not totally exclude it. In addition, the high level of statistical significance observed between responders and controls reduces the likelihood of a false positive/chance finding.
In conclusion, the results presented above strongly suggest that allele T of the MTHFR gene might be a susceptibility risk factor for schizophrenia. Moreover, it may help predict a favorable prognosis for some patients. Prospective longitudinal studies of patients with first-episode schizophrenia treated with neuroleptics are desirable, feasible and needed to test this hypothesis.
Methods

Selection of patients
The criteria used to define response/nonresponse to neuroleptics and the procedures used to recruit and assess patients and controls have been described previously. 18 Briefly, nonresponder patients were characterized by non-remitting psychotic symptoms in spite of adequate treatment with conventional neuroleptics in the 5 years preceding their inclusion in the study. The criteria of resistance to neuroleptics were derived from those of Kane et al. 19 Responder patients were characterized by complete or quasi-complete remission of psychotic symptoms whenever they are treated with conventional neuroleptics. All responder patients experienced at least one psychotic relapse when neuroleptic medication was reduced or discontinued.
Controls were 90 subjects screened for DSM-IV axis I mental disorders using the DIGS.
All patients and controls were Caucasian with European ancestors with a majority (52%) of French Canadians. All participating subjects gave their informed consent. Consent was obtained from both the patient and the legal guardian for incompetent patients. The
Molecular Psychiatry project was approved by the Research Ethics Board of each participating institution.
Genetic analysis
Genomic DNA was isolated from peripheral lymphocytes using standard methods. The target sequence was amplified by PCR using the procedure of Frosst et al. 5 PCR products were digested with HinfI since the mutation creates a HinfI recognition sequence. The PCR product of 198 bp is digested into fragments of 175 bp and 23 bp in the presence of the mutant (valine) allele. The wild-type (alanine) allele remains undigested (198 bp). PCR products were electrophoresed on 9% polyacrylamide gels and photographed. Genotyping and scoring were performed by someone blind to the diagnosis.
Statistical analysis
We compared the allele frequencies in the groups of affected subjects (R and NR) and controls using a Chisquare statistic with 1 degree of freedom. Because we observed a statistically significant difference between patients and controls in the frequency of allele T, we subsequently conducted pair-wise comparisons between the three groups of subjects. Since both case and control groups included a high percentage of subjects with French Canadian ancestry, we reanalyzed our data after stratifying subjects according to the background of their parents (both parents French Canadian vs at least one parent with non-French Canadian ancestry).
